Soligenix, Inc. (NASDAQ:SNGX – Get Free Report) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 67,700 shares, a decrease of 80.9% from the February 29th total of 354,500 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 0.1 days.
Soligenix Price Performance
Shares of Soligenix stock traded down $0.01 during midday trading on Thursday, hitting $0.59. The company’s stock had a trading volume of 55,832 shares, compared to its average volume of 1,232,320. The stock has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $0.61. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.52 and a current ratio of 1.55. Soligenix has a 1-year low of $0.38 and a 1-year high of $4.20.
Soligenix (NASDAQ:SNGX – Get Free Report) last issued its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative return on equity of 251.07%. As a group, equities research analysts predict that Soligenix will post 0.81 EPS for the current year.
Institutional Investors Weigh In On Soligenix
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Recommended Stories
- Five stocks we like better than Soligenix
- How to invest in blue chip stocks
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Use the MarketBeat Stock Screener
- Disney Stock Catches 3 Upgrades In a Single Week
- Stock Analyst Ratings and Canadian Analyst Ratings
- Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.